Micelle BioPharma Inc. will present new research data from the Phase 2 study (SCOT trial) on SC411 (Altemia) at the 2018 American Society Pediatric Hematology and Oncology (ASPHO) meeting, being held in Pittsburgh, PA , May 2-5, 2018.

HOW WE ARE FIGHTING SICKLE CELL ANEMIA

The Centers for Disease Control and Prevention estimates that SCD affects 1 out of every 365 black or African-American babies, and 1 out of every 16,300 Hispanic-American babies.

Working with Congress to improve understanding and work for affordable solutions.

Symptoms of sickle cell disease usually begin in early childhood. Symptoms vary in intensity from person to person, a result of a complex interplay of genetics, cellular and environmental factors. Beginning in childhood, patients with sickle cell disease suffer recurrent crises of severe pain. These crises are unpredictable and are caused by blocked blood flow to organs and extremities.

Signs and symptoms of sickle cell disease usually begin in
early childhood. The severity of symptoms varies from person to person and it has been postulated that clinical manifestations result from complex combinations of genetic, cellular and environmental factors. Some people have mild symptoms, while others are frequently hospitalized for more serious complications. Beginning in childhood, patients suffer unpredictable and recurrent episodes or crises of severe pain due to blocked blood flow to organs and extremities, which often lead to psycho-social and physical disability.